Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

This study is testing whether giving a combination of a targeted blood vessel treatment (TACE — a procedure that blocks tumor blood supply) along with two immunotherapy drugs (atezolizumab and bevacizumab) before surgery can reduce the chances of liver cancer coming back in people who have high-risk features. **You may be eligible if...** - You are 18 to 75 years old with a biopsy-confirmed diagnosis of hepatocellular carcinoma (liver cancer) - Your cancer can be surgically removed, but you have features that make recurrence more likely — such as tumor larger than 5 cm, more than 3 tumors, blood vessel invasion, or poorly differentiated (aggressive) cancer cells - You have not received any prior cancer treatment **You may NOT be eligible if...** - Your cancer has already spread beyond the liver - You have poor liver function or other conditions making surgery unsafe - You have had previous liver cancer treatment Talk to your doctor to see if this trial is right for you.